This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-GD2 scFv-Fc to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the GD2 as well as the biological activity of IL2. The fusion protein improved Fc-Receptor binding and improved ADCC effector function, is useful in the treatment of GD2-expressing cancers in dogs. This immunocytokine was designed for treating GD2-expressing cancers.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-770-sdAb | Recombinant Anti-Human GD2 VHH Single Domain Antibody | Neut, ChiP, IP, FUNC | Llama VHH |
There are currently no Customer reviews or questions for ACFP-SH003. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.